AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for...
Clinical trial results
Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical...
InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the oral presentation of results from the...
TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis
Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...
Zhejiang Huahai’s HB0034 Meets Primary Endpoint in GPP Study
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its multi-center, double-blinded, randomized, placebo-parallel...
AstraZeneca and Daiichi Sankyo’s Enhertu Shows Positive Results in Phase III Study
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the...
AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study
AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...
AstraZeneca’s Camizestrant Shows Promise in SERENA-6 Breast Cancer Study
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III...
Bayer’s Gadoquatrane Shows Positive Results in Phase III QUANTI CNS Study
German pharmaceutical giant Bayer (ETR: BAYN) announced positive results from the Phase III QUANTI CNS...
InnoCare Pharma’s Orelabrutinib Shows Efficacy in RRMS at ACTRIMS Forum
Beijing-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the presentation of Phase II study results...
QYuns Therapeutics’ QX002N Meets Primary Endpoint in AS Phase III Study
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that its Phase III study of...
Coherent Biopharma’s CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer
Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), announced that the U.S....
Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...
Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy
China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical...
J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction
U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...
Bristol-Myers Squibb’s Opdivo Shows Survival Benefit in CheckMate-816 Study
Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from...
TAHO Pharma’s TAH3311 Oral Film Shows Bioequivalence to Eliquis in Study
Taiwan-based TAHO Pharmaceuticals announced positive preliminary results from a pivotal study for its TAH3311 oral...
Bristol-Myers Squibb Releases Five-Year Data on Sotyktu’s Long-Term Efficacy and Safety
In a recent announcement, US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) unveiled the latest...
AccurEdit’s ART002 Becomes First In Vivo Gene Editing Product to Reduce LDL-C in Humans
Suzhou-based gene editing specialist AccurEdit Therapeutics announced that its in vivo gene editing product, ART002,...
Huadong Medicine’s HDM1005 Shows Positive Results in Phase Ia/Ib Study
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced positive results from the Phase Ia/Ib study...